Dry powder inhalers for optimal drug delivery.

Published on Jan 1, 2004in Expert Opinion on Biological Therapy3.224
· DOI :10.1517/14712598.4.1.23
Stephen P. Newman27
Estimated H-index: 27
(University of Nottingham)
Dry powder inhalers (DPIs) have been available for delivering drugs to the lungs for over 30 years. In the last decade there has been a big increase in DPI development, resulting partly from recognised limitations in other types of inhaler device. Many companies are developing DPIs for asthma and chronic obstructive pulmonary disease (COPD) therapy, and there is increasing recognition of the potential role of DPI systems for other therapies, such as inhaled antibiotics and peptides/proteins. Optimised drug delivery may be achieved not only by improvements to devices, but also via more sophisticated formulations that disperse easily in the inhaled air-stream and which may often be delivered by relatively simple inhaler devices. DPIs could become the device category of choice for a wide range of inhaled therapies, involving both local and systemic drug delivery.
📖 Papers frequently viewed together
206 Citations
245 Citations
198 Citations
The purpose of this study was to evaluate the in vitro and in vivo dose delivery characteristics of the AIR® pulmonary delivery system over a range of flow rates. A 5-mg placebo powder of engineered particles with low densities ( 5 μm) was delivered via a simple, capsule based, passive dry powder inhaler. The emitted dose, geometric and aerodynamic particle size distributions (aPSDs) were obtained over a range of flow rates (15–60 LPM). The in vitro results demonstrated improved powder dispersio...
38 CitationsSource
#1Michael T. NewhouseH-Index: 62
#2Peter H. Hirst (University of Nottingham)H-Index: 17
Last. Jeffry G. WeersH-Index: 30
view all 7 authors...
Study objectives: To evaluate the efficiency and reproducibility of pulmonary delivery of an investigational tobramycin PulmoSphere formulation (PStob) [Inhale Therapeutic Systems; San Carlos, CA] by a passive dry powder inhaler, and to compare serum concentrations and whole-lung deposition with a commercial nebulized tobramycin product (TOBI; Chiron Corporation; Seattle, WA). Design: A five-period, open-label, nonrandomized crossover study. Participants: Fourteen healthy volunteers were studied...
168 CitationsSource
#1Ian J. Smith (The Hertz Corporation)H-Index: 3
#2Mark Parry-Billings (The Hertz Corporation)H-Index: 3
Abstract International agreements to ban the use of environmentally damaging chlorofluorocarbons (CFCs) have signalled an end to the traditional CFC-propelled pressurised metered dose inhaler (pMDI) which has long been the mainstay of topical asthma therapy. The need for acceptable and cost-effective replacement inhalers, combined with opportunities to develop generic formulations of patent-expired drugs, has fuelled a lively response from the pharmaceutical industry. Improvements in pMDI design...
134 CitationsSource
#1Steve Newman (University of Nottingham)H-Index: 16
#2S. Malik (University of Nottingham)H-Index: 1
Last. W. FleischerH-Index: 1
view all 8 authors...
Abstract The MAGhaler (Mundipharma GmbH) is a multidose dry powder inhaler (DPI) containing a novel formulation of drug and lactose compacted by an isostatic pressing technique (GGU GmbH). On actuation, a precise dose is metered from a compacted ring-shaped drug tablet. In this study, the lung deposition of salbutamol from this device has been assessed. Ten healthy non-smoking subjects completed a two-way cross-over study, assessing the pulmonary deposition of salbutamol (200 μg) from the MAGhal...
24 CitationsSource
#1Craig Dunbar (Alkermes)H-Index: 6
#2Gerhard ScheuchH-Index: 28
Last. Rick Batycky (Alkermes)H-Index: 1
view all 6 authors...
Abstract The purpose of this study was to evaluate the in vitro and in vivo dose delivery characteristics of two large porous particle placebo formulations with different mass median aerodynamic diameters (MMAD approximately equal to 3 and 5 μm). In vitro dose delivery characteristics were measured using the multistage liquid impinger (MSLI). In vitro lung deposition was predicted by calculating the extrathoracic deposition using the ICRP model, with the remaining fraction assumed to deposit in ...
80 CitationsSource
#1Peter H. Hirst (University of Nottingham)H-Index: 17
#2Steve Newman (University of Nottingham)H-Index: 16
Last. M.G.L HertogH-Index: 1
view all 4 authors...
Abstract The deposition of budesonide at fast (60 l min −1 ) and slow (30 l min −1 ) inspiratory flow rates from Airmax TM , a new multi-dose dry powder inhaler, was compared with that from Turbuhaler ® and a standard pressurized metered dose inhaler (pMDI). Twelve patients with mild to moderate asthma took part in a five-way randomized cross-over study, and inhaled a single nominal dose of 200 μ g budesonide, labelled with 99m Tc, on each study day. Deposition was determined by gamma scintigrap...
23 CitationsSource
#1Sarma DudduH-Index: 12
#2Steven A. SiskH-Index: 1
Last. Jeffry G. WeersH-Index: 30
view all 12 authors...
Purpose. To assess the pulmonary deposition and pharmacokinetics of an engineered PulmoSphere® powder relative to standard micronized drug when delivered from passive dry powder inhalers (DPIs).
135 CitationsSource
#1Steve Newman (University of Nottingham)H-Index: 16
#2William W. Busse (UW: University of Wisconsin-Madison)H-Index: 131
Abstract Many companies are now prioritizing the development of dry powder inhalers (DPIs) above pressurized formulations of asthma drugs. A well-designed DPI and an appropriate powder formulation can optimize the effectiveness of inhaled drug therapy. A DPI must be able to deliver medications effectively for most patients, and an ideal inhaler would provide a dose that does not vary with inspiratory flow rate. Recent regulatory guidelines, among which the U.S.FDA draft guidance is the most stri...
245 CitationsSource
4 CitationsSource
#1Umesh G. Lalloo (University of Natal)H-Index: 37
Abstract Inhaled corticosteroids reduce airway inflammation and bronchial hyper-responsiveness in asthma. Their regular use is associated with a reduction in morbidity and mortality from asthma. International guidelines recommend their use as f rst-line treatment in asthma and the dose should be increased stepwise in accordance with asthma severity. Short-acting β 2 -agonists are recommended for use as reliever medication for the acute relief of symptoms. Long-acting β 2 -agonists have a sustain...
5 CitationsSource
Cited By66
#1Marco Contoli (University of Ferrara)H-Index: 28
#2Sara Barile (Chiesi Farmaceutici S.p.A.)
Last. Fulvio Braido (UniGe: University of Genoa)H-Index: 31
view all 5 authors...
Introduction: The quality of life (QoL) and device needs have not been characterized in asthmatic patients treated via dry powder inhalers (DPIs). The aim of this study was to assess the impact of asthma on health-related QoL, device satisfaction and preference in adult asthmatic patients using DPI devices, and to identify any DPI-associated unmet needs.Methods: An online survey was conducted between November and December 2019 on eligible patients from the Cint consumer panel across Europe. Newl...
#1Hana Douafer (AMU: Aix-Marseille University)H-Index: 4
#2Véronique Andrieu (AMU: Aix-Marseille University)H-Index: 13
Last. Jean Michel Brunel (AMU: Aix-Marseille University)H-Index: 33
view all 3 authors...
Abstract The rise of antimicrobial resistance has created an urgent need for the development of new methods for antibiotics delivery to patients with pulmonary infections in order to mainly increase the effectiveness of the drugs administration, to minimize the risk of emergence of resistant strains, and to prevent patients reinfection. Since bacterial resistance is often related to antibiotic concentration, their pulmonary administration could eradicate strains resistant to the same drug at the...
6 CitationsSource
#1Federico Lavorini (UniFI: University of Florence)H-Index: 30
#2A. BiancoH-Index: 1
Last. G.W. Canonica (Humanitas University)H-Index: 7
view all 15 authors...
Abstract Background The choice of inhaler device for asthma patients depends upon multiple attributes. We investigated factors that may drive general practitioners (GPs) and respiratory specialists in the prescription of inhaler devices for asthma patients who initiated inhalation therapy. Methods We retrospectively analysed prescriptions by GPs and respiratory specialists to asthma patients commencing inhaled corticosteroid/long-acting β2-agonist combination therapy available as both pressurise...
2 CitationsSource
#1Hideyuki Sato (University of Shizuoka)H-Index: 15
#2Aiko Tabata (University of Shizuoka)H-Index: 2
Last. Satomi Onoue (University of Shizuoka)H-Index: 30
view all 7 authors...
The present study aimed to develop inhalable poly (lactic-co-glycolic acid) (PLGA)-based microparticles of salmon calcitonin (sCT) for sustained pharmacological action by the fine droplet drying (FDD) process, a novel powderization technique employing printing technologies. PLGA was selected as a biodegradable carrier polymer for sustained-release particles of sCT (sCT/SR), and physicochemical characterizations of sCT/SR were conducted. To estimate the in vivo efficacy of the sCT/SR respirable p...
1 CitationsSource
#1Takashi Iwanaga (Kindai University)H-Index: 14
#2Yuji Tohda (Kindai University)H-Index: 22
Last. Yasunori Suga (Boehringer Ingelheim)H-Index: 2
view all 4 authors...
Successful treatment for respiratory diseases relies on effective delivery of medication to the lungs using an inhalation device. Different inhalers have distinct characteristics affecting drug administration and patient adherence, which can impact clinical outcomes. We report on the development of the Respimat® soft mist inhaler (SMI) and compare key attributes with metered-dose inhalers (MDIs) and dry powder inhalers (DPIs). The Respimat SMI, a pocket-sized device generating a single-breath, i...
14 CitationsSource
#1Mostafa Mohammadian (IAU: Islamic Azad University)H-Index: 7
#2O. Pourmehran (University of Adelaide)H-Index: 18
Targeted drug delivery is an impressive topic that attracted the attention of many scientists in various scientific communities. Magnetic drug targeting is one of the targeted drug delivery techniques, which uses the magnetic field to externally control the magnetic drug particles. In this study, we aim to assess the magnetic drug delivery to the human respiratory system using a new aerosolization technique driven by surface acoustic waves (SAWs) into a realistic lung model geometrically reconst...
8 CitationsSource
#1Akshay ChandelH-Index: 1
#2Amit K. GoyalH-Index: 48
Last. Goutam RathH-Index: 35
view all 4 authors...
Abstract Pulmonary route is extensively studied for the diagnosis and treatment of pulmonary and extra pulmonary disease conditions such as asthma, tuberculosis, emphysema, and bronchitis. Formulation design, inhalation device and particle size play key role in determining the aerosol performance. The lack of desired clinical outcome along with the problem regarding efficacy or any adverse drug effect may arise due to improper training and education in use of the device to control the actuation ...
39 CitationsSource
#1Dong-Xiao Hong (ZJU: Zhejiang University)H-Index: 2
#2Yu-Long Yun (ZJU: Zhejiang University)H-Index: 1
Last. Shan-Jing Yao (ZJU: Zhejiang University)H-Index: 34
view all 4 authors...
Abstract Parathyroid hormone (PTH1–34)-loaded dry powders were fabricated from aqueous solution for pulmonary administration using supercritical fluid assisted atomization introduced by a hydrodynamic cavitation mixer (SAA-HCM). Herein, chitosan oligosaccharide (CSO) was selected as a carrier in an effort to enhance transmucosal absorption of the drug. Well-defined, separated and spherical PTH(1–34)/CSO composite microparticles were obtained, and the particles size could be well controlled with ...
9 CitationsSource
#1Morteza Yousefi (RMIT: RMIT University)H-Index: 4
#2O. Pourmehran (BNUT: Babol Noshirvani University of Technology)H-Index: 18
Last. Jiyuan Tu (RMIT: RMIT University)H-Index: 47
view all 6 authors...
Administration of drug in the form of particles through inhalation is generally preferable in the treatment of respiratory disorders. Conventional inhalation therapy devices such as inhalers and nebulizers, nevertheless, suffer from low delivery efficiencies, wherein only a small fraction of the inhaled drug reaches the lower respiratory tract. This is primarily because these devices are not able to produce a sufficiently fine drug mist that has aerodynamic diameters on the order of a few micron...
38 CitationsSource